1 Avenue de Lafayette,

Boston,

MA,

USA,

ZIP: 02111

Phone:

The Inborn Errors of Metabolism team understands that there is still huge value to the inherited metabolic disease community in providing a platform for knowledge sharing and scientific corroboration. As such, the Inborn Errors of Metabolism Drug Development summit has returning to physicality for the 2nd year!

Join colleagues from across the inherited metabolic disease drug developer field and KOLs from industry, academia, and patient advocacy to learn how the major roadblocks to accelerated drug production are being overcome. This summit will serve as a discussion forum to look at where cutting-edge gene therapy modalities interact with existing treatment options, as well as how diseases can be best targeted to treat the huge unmet medical need for rare metabolic diseases.

The potential for biopharma to innovate, actively drive progress and change lives through the provision of treatments of various modalities is growing.

For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety, and commercial viability.

This is your comprehensive guide to define your drug development path for 2021. Don't miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.

Prices:

Primary Pricing - Conference + 2 Workshops: USD 3997.00,
Primary Pricing - Conference + 1 Workshop: USD 3498.00,
Primary Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + 2 Workshops: USD 3397.00,
Academic Pricing - Conference + 1 Workshop: USD 2998.00,
Academic Pricing - Conference Only: USD 2599.00,
Vendor Pricing - Conference + 2 Workshops: USD 4797.00,
Vendor Pricing - Conference + 1 Workshop: USD 4198.00,
Vendor Pricing - Conference Only: USD 3599.00

URLs:

Tickets: https://go.evvnt.com/822253-0?pid=1052

Brochure: https://go.evvnt.com/822253-3?pid=1052

Heather Lau, Assistant Professor, Department of Neurology, Associate Director, Division of Neurogenetics, Director, Lysosomal Storage Disease Program, NYU Grossman School of Medicine, Noa Sher, Chief Scientist, Minovia Therapeutics, Yves Sabbagh, SVP and Chief Scientific Officer, Inozyme Pharma, Antonio Nin, Vice President - Clinical Development, Ultragenyx Pharmaceutical Inc, Karsten Baumgaertel, Director of Translational Biology, Travere Therapeutics, Tom Pulles, Vice President and Head of Medical Affairs and Patient Advocacy, EMEA, Ultragenyx Pharmaceutical Inc, Asif Paker, Vice President - Clinical Development, SwanBio Therapeutics, Deya Corzo, Executive Vice President and Chief Medical Officer, Sigilon Inc., Ekaterina Wright, Senior Director - Global Medical and Rare Diseases Lead, Takeda Pharmaceutical Co. Ltd., Kate Cygnar, Associate Director - Genome Engineering Technologies, Regeneron Pharmaceuticals, Kent Christopherson, Senior Director, Medical Affairs, Orchard Therapeutics, Takashi Kei, Kishimoto Chief Scientific Officer, Selecta Biosciences Inc., Joslyn Crowe, Executive Director, National Niemann Pick Disease Foundation, Kazunori Tanizawa, Executive Director of Development, JCR Pharmaceuticals, Terri Klein, President and Chief Executive Officer, National MPS Society, Adam Silverman, Director of Therapeutics, Discovery Codexis, Alfica Sehgal, Vice President of Discovery, CAMP4 Therapeutics, Sean Burns, Senior Director - Disease Biology, Intellia Therapeutics, Chris Mason, Founder and Chief Scientific Officer, AVROBIO, Jose Gomez, SVP, Global Market Access, AVROBIO, Mathias Schmidt, Chief Executive Officer, Armagen TechnologiesInc, Jodie Gillon, Chief Patient Officer, Abeona Therapeutics